FDA OKs Qiagen's companion Dx tool to lung-cancer drug

07/15/2013 | Genetic Engineering & Biotechnology News

The FDA has approved Qiagen's Therascreen EGFR assay as a companion diagnostic to determine which patients are eligible to receive Boehringer Ingelheim's Gilotrif. Gilotrif, or afatinib, is a newly approved drug for patients with metastatic nonsmall-cell lung cancer who have exon 21 L858R substitution mutations and exon 19 deletions in the EGFR gene.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ